ReviewGut2026
From preclinical phase of Crohn's disease to postoperative recurrence: shared mechanisms and potential interventions.
Review in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cxcl9 as a Marker of Adipose Tissue Changes Caused by Bariatric Surgery and Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with high risk of surgery. Despite advances in medical treatment, of those patients who undergo ileocolonic resections, up to 70% of patients experience postoperative recurrence (POR) within 1 year of surgery. This underscores the need for a better understanding of the pathogenesis of POR. We hypothesise that the transient 'disease-free' state following surgical resection biologically mirrors the earliest preclinical stages of new-onset CD and that shared biomarkers across preclinical and postoperative settings reflect common pathogenic pathways. Identifying these shared signatures may offer a unique opportunity to elucidate mechanisms underlying both disease initiation and recurrence and to inform strategies aimed at prevention of new onset CD as well as POR. In this review, we synthesise insights from recent biomarker and multiomics studies spanning preclinical and postoperative CD cohorts. We highlight predictive biomarkers shared across CD onset and POR, including genetic variants, immune mediators such as CXCL9 and interleukin 6, microbial signatures involving
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.